Dottikon ES Holding Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Dottikon ES Holding is de winst gegroeid met een gemiddeld jaarlijks percentage van 26.9%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 13.1%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 17.5% per jaar. Het rendement op eigen vermogen van Dottikon ES Holding is 9.1%, en het heeft een nettomarge van 24.2%.
Belangrijke informatie
26.9%
Groei van de winst
24.4%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 16.3% |
| Inkomstengroei | 17.5% |
| Rendement op eigen vermogen | 9.1% |
| Nettomarge | 24.2% |
| Volgende winstupdate | 29 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
What You Can Learn From Dottikon ES Holding AG's (VTX:DESN) P/E
Oct 19
Dottikon ES Holding AG (VTX:DESN) Not Flying Under The Radar
Jul 17Here's Why Dottikon ES Holding (VTX:DESN) Can Manage Its Debt Responsibly
Jun 26Why Dottikon ES Holding's (VTX:DESN) Shaky Earnings Are Just The Beginning Of Its Problems
Jun 05Subdued Growth No Barrier To Dottikon ES Holding AG's (VTX:DESN) Price
Mar 31Does Dottikon ES Holding (VTX:DESN) Deserve A Spot On Your Watchlist?
Feb 17Earnings Not Telling The Story For Dottikon ES Holding AG (VTX:DESN)
Dec 26Dottikon ES Holding (VTX:DESN) Is Doing The Right Things To Multiply Its Share Price
Nov 10Here's Why We Think Dottikon ES Holding (VTX:DESN) Is Well Worth Watching
Oct 25These 4 Measures Indicate That Dottikon ES Holding (VTX:DESN) Is Using Debt Reasonably Well
Sep 19At CHF217, Is It Time To Put Dottikon ES Holding AG (VTX:DESN) On Your Watch List?
Aug 20If EPS Growth Is Important To You, Dottikon ES Holding (VTX:DESN) Presents An Opportunity
Jul 20Returns Are Gaining Momentum At Dottikon ES Holding (VTX:DESN)
Jul 05Here's Why Dottikon ES Holding (VTX:DESN) Can Manage Its Debt Responsibly
Jun 17Is It Too Late To Consider Buying Dottikon Es Holding AG (VTX:DESN)?
Apr 07Dottikon Es Holding's (VTX:DESN) Returns Have Hit A Wall
Mar 22Should You Be Adding Dottikon Es Holding (VTX:DESN) To Your Watchlist Today?
Mar 06Is It Too Late To Consider Buying Dottikon Es Holding AG (VTX:DESN)?
Jan 04Dottikon Es Holding (VTX:DESN) Has More To Do To Multiply In Value Going Forward
Dec 19Does Dottikon Es Holding (VTX:DESN) Deserve A Spot On Your Watchlist?
Dec 02What Does Dottikon Es Holding AG's (VTX:DESN) Share Price Indicate?
Sep 20Here's What To Make Of Dottikon Es Holding's (VTX:DESN) Decelerating Rates Of Return
Sep 02Why Dottikon Es Holding AG (VTX:DESN) Could Be Worth Watching
Jun 20The Returns At Dottikon Es Holding (VTX:DESN) Aren't Growing
Jun 02Does Dottikon Es Holding (VTX:DESN) Deserve A Spot On Your Watchlist?
Apr 11When Should You Buy Dottikon Es Holding AG (VTX:DESN)?
Mar 09Dottikon Es Holding (VTX:DESN) Has More To Do To Multiply In Value Going Forward
Feb 23Do Dottikon Es Holding's (VTX:DESN) Earnings Warrant Your Attention?
Dec 30Dottikon Es Holding's (VTX:DESN) Returns On Capital Are Heading Higher
Nov 24When Should You Buy Dottikon Es Holding AG (VTX:DESN)?
Sep 28Does Dottikon Es Holding (VTX:DESN) Deserve A Spot On Your Watchlist?
Sep 02We Like These Underlying Return On Capital Trends At Dottikon Es Holding (VTX:DESN)
Aug 17When Should You Buy Dottikon Es Holding AG (VTX:DESN)?
Jun 15Here's Why I Think Dottikon Es Holding (VTX:DESN) Is An Interesting Stock
Jun 01Dottikon Es Holding (VTX:DESN) Is Experiencing Growth In Returns On Capital
May 17Could The Dottikon Es Holding AG (VTX:DESN) Ownership Structure Tell Us Something Useful?
Mar 20Is Now The Time To Put Dottikon Es Holding (VTX:DESN) On Your Watchlist?
Mar 01Here’s What’s Happening With Returns At Dottikon Es Holding (VTX:DESN)
Feb 08
If You Had Bought Dottikon Es Holding (VTX:DESN) Shares Five Years Ago You'd Have Earned 856% Returns
Jan 18Is Dottikon Es Holding AG's (VTX:DESN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 29With EPS Growth And More, Dottikon Es Holding (VTX:DESN) Is Interesting
Nov 30Opbrengsten en kosten
Hoe Dottikon ES Holding geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 333 | 81 | 87 | 0 |
| 31 Dec 23 | 339 | 83 | 87 | 0 |
| 31 Mar 23 | 326 | 88 | 84 | 0 |
| 31 Dec 22 | 302 | 81 | 81 | 0 |
| 30 Sep 22 | 284 | 74 | 78 | 0 |
| 30 Jun 22 | 268 | 67 | 77 | 0 |
| 31 Mar 22 | 252 | 59 | 77 | 0 |
| 31 Dec 21 | 240 | 57 | 77 | 0 |
| 30 Sep 21 | 229 | 55 | 77 | 0 |
| 30 Jun 21 | 224 | 54 | 76 | 0 |
| 31 Mar 21 | 219 | 52 | 75 | 0 |
| 31 Dec 20 | 204 | 46 | 73 | 0 |
| 30 Sep 20 | 189 | 39 | 71 | 0 |
| 30 Jun 20 | 182 | 36 | 70 | 0 |
| 31 Mar 20 | 175 | 33 | 69 | 0 |
| 31 Dec 19 | 172 | 31 | 69 | 0 |
| 30 Sep 19 | 169 | 30 | 69 | 0 |
| 30 Jun 19 | 158 | 23 | 68 | 0 |
| 31 Mar 19 | 148 | 16 | 67 | 0 |
| 31 Dec 18 | 147 | 17 | 66 | 0 |
| 30 Sep 18 | 145 | 18 | 65 | 0 |
| 30 Jun 18 | 153 | 22 | 65 | 0 |
| 31 Mar 18 | 161 | 26 | 64 | 0 |
| 31 Dec 17 | 159 | 24 | 60 | 0 |
| 30 Sep 17 | 157 | 22 | 56 | 0 |
| 30 Jun 17 | 156 | 22 | 55 | 0 |
| 31 Mar 17 | 155 | 22 | 53 | 0 |
| 31 Dec 16 | 151 | 22 | 55 | 0 |
| 30 Sep 16 | 148 | 23 | 57 | 0 |
| 30 Jun 16 | 136 | 19 | 55 | 0 |
| 31 Mar 16 | 123 | 14 | 54 | 0 |
| 31 Dec 15 | 113 | 10 | 52 | 0 |
| 30 Sep 15 | 102 | 5 | 51 | 0 |
| 30 Jun 15 | 100 | 3 | 50 | 0 |
| 31 Mar 15 | 98 | 1 | 48 | 0 |
| 31 Dec 14 | 95 | 0 | 47 | 0 |
| 30 Sep 14 | 91 | -1 | 46 | 0 |
| 30 Jun 14 | 91 | -2 | 46 | 0 |
| 31 Mar 14 | 92 | -3 | 46 | 0 |
| 31 Dec 13 | 89 | -5 | 46 | 0 |
Kwaliteitswinsten: DESN heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (24.2%) DESN } zijn lager dan vorig jaar (26.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van DESN is de afgelopen 5 jaar aanzienlijk gegroeid met 26.9% per jaar.
Versnelling van de groei: De winstgroei DESN is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.
Winst versus industrie: DESN had het afgelopen jaar een negatieve winstgroei ( -8.1% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Pharmaceuticals ( 10.2% ).
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 9.1% ) van DESN wordt als laag beschouwd.